Lung Cancer
Latest News
Advertisement
Latest Videos
Advertisement
More News
Risk of Pneumonitis Post-Chemoradiation in Stage 3 NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Considering PD-L1 and EGFR Status With I/O in Stage 3 NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
PACIFIC Trial in Stage 3 NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Future of Neoadjuvant I/O in ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Neoadjuvant I/O for ES NSCLC: Key Trials from ESMO 2020
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Key Trials in Neoadjuvant I/O for ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Role of Neoadjuvant I/O in ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Patient Selection: Adjuvant Therapy and Testing for ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Phase 3 ADAURA Study: EGFR-Mutated NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Role of Postoperative Radiotherapy in Early Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Neoadjuvant Chemotherapy in Early-Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Treatment of Early-Stage NSCLC: Current Standard of Care
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
In an interview with OncLive® Michael Shafique, MD, discusses examples of this groundbreaking research of immunotherapy combinations in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
3
First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL
4
HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer
5